Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
China’s energy crunch threatens pharma supply chains
This
week, PharmaCompass looks at the energy crunch in China and its likely fallout
on the global
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal
This week,
Phispers brings to you the details of the bioelectronics firm formed by GSK and
Google. T
Phispers: Pfizer-Allergan end megamerger, GSK wants to make copying its drugs easier & more
This week, the
biggest news in the world of pharmaceuticals was the termination of the Pfizer-Allerg
Antibiotic resistant superbugs: deadlier than cancer and closer to you than you think
The
global war on superbugs, bacteria that grow
resistant to drugs, infect humans and defy conventio
Haunted: Teva’s $1.2 billion ‘pay-for-delay’ penalty; which companies will get hit next?
Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total payment of
Dr. Reddy’s expansion plans for API production
Unrelated to the inspection of
the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe
